Home > Healthcare > Biotechnology > Biopharma > Gene Vector Market

Gene Vector Market Share

Report ID: GMI5693
Published Date: May 2023
Report Format: PDF

Download Free Sample

Gene Vector Market Share

The Key gene vector market players include :

Cobra Biologics
Fujifilm Diosynth Biotechnologies
SIRION Biotech
Merck KGaA Inc.
Thermo Fisher Scientific.
Lonza
Oxford Biomedica
Novasep
Spark Therapeutics
Kaneka Eurogentec
Finvector Vision Therapies,
Brammer Bio

Moreover, various strategies, such as research and development investments, mergers and acquisitions, and product launches, are being adopted by domestic companies to strengthen their market position. For instance, In July 2021, the company Thermo Fisher Scientific Inc. announced the launch of new cGMP plasmid DNA manufacturing facility in Carlsbad, Calif which will fulfil the growing demand of plasmid DNA-based therapies and viral mRNA-based vaccines.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global market for gene vector crossed USD 1.20 billion in 2022 and will grow at 13.1% CAGR between 2023 and 2032.

Gene vector demand across gene therapy will grow substantially through 2032 due to its increasing use in the treatment of cancer, chronic disease, infectious disease, and blood disorders.

North America gene vector market held 53.8% revenue share in 2022 owing to the presence of a large number of R&D centers and institutes developing advanced gene therapies.

Cobra Biologics, SIRION Biotech, Lonza, Oxford Biomedica, Novasep, Spark Therapeutics, Kaneka Eurogentec, and Brammer Bio are some of the major companies in the market.